Here, we demonstrate that combined anti-PD-1/OX40 mAb inhibited the tumor development in the 10-day established ID8 ovarian cancer model, resulting in the long-lasting survival of 60% of mice while individual mAb was ineffective in tumor protection. Here, TNFRSF4 is linked to ovarian cancer.